Equibles does not estimate personal net worth.
Get an email with a short summary when Aptevo Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get APVO alertsDaniel J. Abdun-Nabi is recorded as Board Member and CEO at Aptevo Therapeutics Inc. (APVO), Board Member at Emergent BioSolutions Inc. (EBS) since May 23, 2012, CEO at Emergent BioSolutions Inc. (EBS) since April 1, 2012 and COO at Emergent BioSolutions Inc. (EBS) since May 16, 2007. The newest filing on record that lists Daniel J. Abdun-Nabi as CEO at Aptevo Therapeutics Inc. (APVO) is dated July 31, 2026. The newest filing on record that lists Daniel J. Abdun-Nabi as Board Member at Aptevo Therapeutics Inc. (APVO) is dated April 20, 2020. Daniel J. Abdun-Nabi was last confirmed as Board Member at REGENXBIO Inc. (RGNX) in a filing dated April 19, 2021. The proxy statement of Emergent BioSolutions Inc. reports total compensation of $633,322 for Daniel J. Abdun-Nabi in fiscal 2019, including a base salary of $300,231. Disclosed compensation is on record for 3 fiscal years. Daniel J. Abdun-Nabi has spoken on 4 earnings calls across 1 company, most recently for Emergent BioSolutions Inc. on May 5, 2016. Emergent BioSolutions Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Aptevo Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Emergent BioSolutions Inc. includes Joseph C. Papa (CEO and Board Member), Joseph Papa (CEO and Board Member), Robert G. Kramer, Sr. (CEO and Board Member) and 7 others.
“During the call today, I will provide a brief summary of our first quarter financial results, give an update on our recent business achievements, and then discuss the upcoming transition to a follow-on BioThrax procurement contract with the CDC.”
“Well thank you, Bob and good afternoon everyone and thank you for joining our call. Today I would like to provide an overview of our 2014 performance, highlight some of our recent business achievements, and lastly discuss our 2015 outlook.”
“And thank you for joining our call today. During my prepared comments, I will briefly touch on our financial performance for Q2 and year-to-date and our guidance for the third quarter and the full year of 2013.”
“In my prepared comments, I will briefly touch on our financial performance for the quarter and our guidance for the full year and the second quarter. I'll then discuss our year-to-date operational performance and highlight the key milestones for the remainder of 2013.”
2012-05-23–present
2012-04-01–present
2007-05-16–present
SEC 8-K
2007-04-01–present
Start not stated–present
Last confirmed April 20, 2020
Start not stated–present
Last confirmed July 31, 2026
2018-05-24–2019-03-31
2016-01-01–2021-04-19
Last confirmed by a filing; no departure on record
Start not stated–2019-03-31
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member, CEO, COO
2007-04-01–present
RGNX
Biotechnology · Healthcare
Board Member
Since 2016-01-01, last confirmed 2021-04-19
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Emergent BioSolutions Inc. (EBS) | Former Chief Executive Officer | $300,231 | $633,322 |
| 2018 | Emergent BioSolutions Inc. (EBS) | Former Chief Executive Officer | $829,160 | $4,100,936 |
| 2017 | Emergent BioSolutions Inc. (EBS) | Former Chief Executive Officer | $819,029 | $3,681,284 |
